{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:44:23Z","timestamp":1782787463932,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is a major clinical problem in elderly patients, yet data on prognostic factors and treatment outcomes in this population remain limited. This study investigated clinical characteristics, treatment patterns, and survival in elderly breast cancer patients, with focus on functional status, comorbidity burden, and inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 261 patients aged\u2009\u2265\u200965 years diagnosed with breast cancer at Dokuz Eyl\u00fcl University Medical Oncology Clinic between 2010 and 2023. Patients were stratified into two age groups (65\u201374 and \u2265\u200975 years). Clinicopathological characteristics, treatment modalities, ECOG performance status, Charlson Comorbidity Index (CCI), and the derived neutrophil-to-lymphocyte ratio (dNLR) were analyzed. Treatment comparisons were restricted to non-metastatic disease (stage I\u2013III,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009204). Survival was analyzed with Kaplan\u2013Meier and log-rank tests. Receiver operating characteristic (ROC) analysis identified an optimal dNLR cutoff, and time-dependent ROC with inverse probability of censoring weighting assessed discriminatory performance over time. Multivariate Cox regression with backward likelihood ratio elimination identified independent prognostic factors; Harrell\u2019s concordance index was calculated for model validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median follow-up was 142 months. No significant differences were observed between age groups regarding pathological features, receptor status, or comorbidities. However, patients aged\u2009\u2265\u200975 years were less likely to undergo primary surgery (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041), adjuvant chemotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), or radiotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Median overall survival was 148 versus 87 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). ROC identified an optimal dNLR cutoff of 1.74 (AUC 0.628); time-dependent AUCs were 0.772, 0.652, and 0.668 at 1, 3, and 5 years. LDH showed no significant discriminatory capacity. Multivariate analysis identified ECOG\u2009\u2265\u20092 (HR 2.89), CCI\u2009\u2265\u20093 (HR 2.12), stage IV (HR 7.43), dNLR\u2009&gt;\u20091.74 (HR 2.14), TNBC (HR 2.30), age\u2009\u2265\u200975 (HR 1.52), and surgery (HR 0.53) as independent predictors of mortality. The full model achieved a C-index of 0.792.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elderly breast cancer patients are less frequently treated despite similar clinicopathological features. ECOG performance status, CCI, disease stage, dNLR, and clinical subtype are independent predictors of mortality. The prognostic impact of chronological age was substantially attenuated after adjusting for functional status and comorbidity, emphasizing that treatment decisions should be guided by comprehensive geriatric assessment rather than age alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16142-8","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:53:51Z","timestamp":1778151231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and survival in elderly breast cancer patients: roles of age, stage and inflammatory markers"],"prefix":"10.1186","volume":"26","author":[{"given":"Do\u011fancan","family":"Akpalamut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil \u0130brahim","family":"Ellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ata\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktay Halit","family":"Aktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin Salih","family":"Semiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Karao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"3","key":"16142_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"16142_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"16142_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JOP.2015.010207","volume":"12","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Hurria A, Muss HB. Breast cancer in women older than 80 years. J Oncol Pract. 2016;12(2):123\u201332. https:\/\/doi.org\/10.1200\/JOP.2015.010207.","journal-title":"J Oncol Pract"},{"issue":"4","key":"16142_CR4","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.14336\/AD.2023.1002","volume":"15","author":"VC Fonseca","year":"2024","unstructured":"Fonseca VC, Sidiropoulou Z. Geriatric breast cancer: Staging, molecular surrogates, and treatment. A review & meta-analysis. Aging Dis. 2024;15(4):1602\u201318. https:\/\/doi.org\/10.14336\/AD.2023.1002.","journal-title":"Aging Dis"},{"issue":"1","key":"16142_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09131-6","volume":"22","author":"L Li","year":"2022","unstructured":"Li L, Ai L, Jia L, Zhang L, Lei B, Zhang Q. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine. BMC Cancer. 2022;22(1):29. https:\/\/doi.org\/10.1186\/s12885-021-09131-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"16142_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10147-014-0672-8","volume":"20","author":"A Dirican","year":"2015","unstructured":"Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol. 2015;20(1):70\u201381. https:\/\/doi.org\/10.1007\/s10147-014-0672-8.","journal-title":"Int J Clin Oncol"},{"key":"16142_CR7","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.2147\/CMAR.S180695","volume":"10","author":"K Ren","year":"2018","unstructured":"Ren K, Yin Y, He F, Shao Y, Wang S. Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer. Cancer Manag Res. 2018;10:4891\u20138. https:\/\/doi.org\/10.2147\/CMAR.S180695.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"16142_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","volume":"54","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961\u201370. https:\/\/doi.org\/10.3109\/0284186X.2015.1043026.","journal-title":"Acta Oncol"},{"issue":"9","key":"16142_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091243","volume":"11","author":"G Pelizzari","year":"2019","unstructured":"Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L, et al. Lactate dehydrogenase (LDH) response to first-line treatment predicts survival in metastatic breast cancer: first clues for a cost-effective and dynamic biomarker. Cancers (Basel). 2019;11(9):1243. https:\/\/doi.org\/10.3390\/cancers11091243.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"16142_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-017-4448-5","volume":"166","author":"M Lodi","year":"2017","unstructured":"Lodi M, Scheer L, Reix N, Heitz D, Carin AJ, Thi\u00e9baut N, et al. Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat. 2017;166(3):657\u201368. https:\/\/doi.org\/10.1007\/s10549-017-4448-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"16142_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10549-019-05356-z","volume":"178","author":"N de Glas","year":"2019","unstructured":"de Glas N, Bastiaannet E, de Boer A, Siesling S, Liefers GJ, Portielje J. Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study. Breast Cancer Res Treat. 2019;178(1):141\u20139. https:\/\/doi.org\/10.1007\/s10549-019-05356-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"16142_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10549-010-0898-8","volume":"124","author":"E Bastiaannet","year":"2010","unstructured":"Bastiaannet E, Liefers GJ, de Craen AJ, Kuppen PJ, van de Water W, Portielje JE, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124(3):801\u20137. https:\/\/doi.org\/10.1007\/s10549-010-0898-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"16142_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040958","volume":"12","author":"I Corbeau","year":"2020","unstructured":"Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers (Basel). 2020;12(4):958. https:\/\/doi.org\/10.3390\/cancers12040958.","journal-title":"Cancers (Basel)"},{"issue":"35","key":"16142_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011898","volume":"97","author":"SK Geng","year":"2018","unstructured":"Geng SK, Fu SM, Fu YP, Zhang HW. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection. Medicine (Baltimore). 2018;97(35):e11898. https:\/\/doi.org\/10.1097\/MD.0000000000011898.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"16142_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13277-015-3805-4","volume":"37","author":"S Krenn-Pilko","year":"2016","unstructured":"Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumor Biol. 2016;37(1):361\u20138. https:\/\/doi.org\/10.1007\/s13277-015-3805-4.","journal-title":"Tumor Biol"},{"issue":"3","key":"16142_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s43018-025-00924-3","volume":"6","author":"S Camargo","year":"2025","unstructured":"Camargo S, Moskowitz O, Giladi A, Levinson M, Balaban R, Gola S, et al. Neutrophils physically interact with tumor cells to form a signaling niche promoting breast cancer aggressiveness. Nat Cancer. 2025;6(3):540\u201358.","journal-title":"Nat Cancer"},{"key":"16142_CR17","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8:1960. PMID: 29375577; PMCID: PMC5767595.","journal-title":"Front Immunol"},{"issue":"5","key":"16142_CR18","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1200\/JOP.2014.001457","volume":"10","author":"RW Jang","year":"2014","unstructured":"Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E, et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014;10(5):e335-41. https:\/\/doi.org\/10.1200\/JOP.2014.001457.","journal-title":"J Oncol Pract"},{"key":"16142_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/CIA.S414727","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhong Y, Zhou Y, Mao F, Zhang X, Wang C, et al. The prognostic value of the age-adjusted Charlson Comorbidity Index among the elderly with breast cancer. Clin Interv Aging. 2023;18:1163\u201374. https:\/\/doi.org\/10.2147\/CIA.S414727.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"16142_CR20","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/S1470-2045(11)70383-7","volume":"13","author":"L Biganzoli","year":"2012","unstructured":"Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148-60. https:\/\/doi.org\/10.1016\/S1470-2045(11)70383-7.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16142-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:09:42Z","timestamp":1782785382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16142"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16142-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8909658\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of Dokuz Eyl\u00fcl University (Approval No: 2023\/13\u201313, 26 April 2023). Due to the retrospective design of the study, the requirement for informed consent was waived by the Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"784"}}